PKR Recombinant Rabbit monoclonal Antibody IgG
Fig1: Western blot analysis of PKR on different lysates using anti-PKR antibody at 1/1,000 dilution.
Lane 1: MCF-7
Lane 2: Hela
Fig2: ICC staining PKR in MCF-7 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Fig3: Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-PKR antibody. Counter stained with hematoxylin.
Host Species; Species ReactivityRabbit; Human
Application SummaryWB, ICC/IF, IHC, IP
Purification; FormulationProA affinity purified; 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.
ALTnamesInterferon-induced, double-stranded RNA-activated protein kinase, Eukaryotic translation initiation factor 2-alpha kinase 2, Interferon-inducible RNA-dependent protein kinase, P1/eIF-2A protein kinase, Protein kinase RNA-activated, Tyrosine-protein kinase EIF2AK2, p68 kinase
BackgroundAn interferon-inducible, RNA-dependent protein serine/threonine kinase (PKR) has been described. PKR in earlier literature is variously known as DAI, dsJ, PI kinase, p65, p67 or TIK for the mouse kinase; and p68 or p69 for the human kinase. The PKR kinase substrate is the a subunit of protein synthesis initiation factor eIF-2. Phosphorylation of eIF-2a on serine-51 results in inhibition of translation. Molecular cDNA clones have been isolated from both human and mouse cells. The serine/threonine kinase catalytic domains map to the carboxy terminal half of the protein while the RNA-binding domains are located in the amino terminal region. Three kinds of regulation of PKR enzymatic activity have been described. These include transcriptional regulation in response to interferon, an autoregulatory mechanism controlling PKR expression at the level of translation and post-translational regulation by RNA mediated autophosphorylation.(ET1610-84)